A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis
Phase of Trial: Phase III
Latest Information Update: 18 Feb 2018
Price : $35 *
At a glance
- Drugs Etelcalcetide (Primary)
- Indications Secondary hyperparathyroidism
- Focus Adverse reactions; Registrational
- Sponsors Amgen; KAI Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 11 Jul 2017 Status changed from active, no longer recruiting to completed.
- 03 Mar 2017 This trial is completed in Germany.